<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03623698</url>
  </required_header>
  <id_info>
    <org_study_id>18IC4403</org_study_id>
    <nct_id>NCT03623698</nct_id>
  </id_info>
  <brief_title>Nebulised Hypertonic Saline in Children and Young People With Neuromuscular Disease and Cerebral Palsy</brief_title>
  <official_title>A Chart Review Assessing the Effects of Nebulised Hypertonic Saline on Respiratory-related Complications in Children and Young People With Neuromuscular Disease and Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pneumonia, respiratory exacerbations, and chronic pulmonary infection are important causes of&#xD;
      emergency admissions, hospitalisations and death in children with Neuromuscular disorders and&#xD;
      Cerebral Palsy. Hence, there is a need for research on how to therapeutically aid airway&#xD;
      clearance and decrease respiratory exacerbations. Studies have shown that nebulised&#xD;
      Hypertonic Saline is well tolerated, reduces pulmonary exacerbations and improves lung&#xD;
      function and Lung Clearance Index in patients with Cystic Fibrosis, and enhances mucociliary&#xD;
      clearance in asthmatic patients. Nevertheless, to the investigators' knowledge, there is no&#xD;
      available data concerning the use of nebulised Hypertonic Saline in the management of&#xD;
      children with Neuromuscular disorders and Cerebral Palsy. This study aims to assess the&#xD;
      effectiveness of nebulised Hypertonic Saline to decrease hospitalisations and courses of&#xD;
      antibiotics in children with Neuromuscular disorders and Cerebral Palsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chart review of children and young people with Neuromuscular disease or Cerebral Palsy who&#xD;
      are cared for in the Royal Brompton Hospital and that have been treated with nebulised&#xD;
      hypertonic saline for at least 12 months.&#xD;
&#xD;
      To further complement data from hospital records, two questionnaires will be applied. Parents&#xD;
      of children who meet criteria will be asked to complete the following questionnaires:&#xD;
&#xD;
        1. The National Health and Nutrition Examination Survey (NHANES) for Hospitalisation and&#xD;
           access to are - HUQ.010Í¾ and&#xD;
&#xD;
        2. Questionnaire on Hypertonic Saline treatment.&#xD;
&#xD;
      Children from 10 - 18 years will be asked to complete the Questionnaire on Hypertonic Saline&#xD;
      treatment.&#xD;
&#xD;
      AIMS&#xD;
&#xD;
        1. Explore whether treatment with nebulised Hypertonic Saline in children with&#xD;
           Neuromuscular disease or Cerebral Palsy decreases respiratory-related complications.&#xD;
&#xD;
        2. Evaluate whether the treatment with nebulised hypertonic saline in children with&#xD;
           neuromuscular disease or cerebral palsy improves the ease of airway clearance.&#xD;
&#xD;
        3. Explore how parents of children with Neuromuscular disease and children with Cerebral&#xD;
           Palsy perceive the treatment with nebulised hypertonic saline compared with previous&#xD;
           management.&#xD;
&#xD;
      Sample Size:&#xD;
&#xD;
      The investigators aim to recruit 40 participants for each group, including children and young&#xD;
      people and their parents or legal guardians, as this is a pilot study.&#xD;
&#xD;
      STATISTICAL ANALYSIS PLAN&#xD;
&#xD;
        -  Univariate X2 analysis for categorical variables to investigate Courses of antibiotic&#xD;
           treatment.&#xD;
&#xD;
        -  Univariate X2 analysis for categorical variables to investigate Number of&#xD;
           hospitalisations.&#xD;
&#xD;
        -  Student t testing will be used to analyse nocturnal oxygenation and ventilation outcomes&#xD;
           comparing one year before and after starting treatment with Hypertonic Saline.&#xD;
&#xD;
        -  Independent t testing and Mann-Whitney U test to analyse Rate of decline in pulmonary&#xD;
           function.&#xD;
&#xD;
        -  Cox proportional hazard model to test differences in primary endpoints for different&#xD;
           baseline FVC.&#xD;
&#xD;
        -  Univarate analysis to analyse Ease of airway clearance.&#xD;
&#xD;
        -  Univariate analysis on perception of treatment.&#xD;
&#xD;
      Data and all appropriate documentation will be stored for a minimum of 10 years after the&#xD;
      completion of the study, including the follow-up period.&#xD;
&#xD;
      ETHICS APPROVAL The Study Coordination Centre has obtained approval from the Yorkshire &amp; The&#xD;
      Humber - Leeds West Research Ethics Committee (REC) and Health Regulatory Authority (HRA).&#xD;
      The study also received confirmation of capacity and capability from each participating NHS&#xD;
      Trust before accepting participants into the study or any research activity was carried out.&#xD;
      The study will be conducted in accordance with the recommendations for physicians involved in&#xD;
      research on human subjects adopted by the 18th World Medical Assembly, Helsinki 1964 and&#xD;
      later revisions.&#xD;
&#xD;
      CONSENT Consent to enter the study must be sought from each participant only after a full&#xD;
      explanation has been given, an information leaflet offered and time allowed for&#xD;
      consideration. Signed participant consent should be obtained. The right of the participant to&#xD;
      refuse to participate without giving reasons must be respected. After the participant has&#xD;
      entered the study the clinician remains free to give alternative treatment to that specified&#xD;
      in the protocol at any stage if he/she feels it is in the participant's best interest, but&#xD;
      the reasons for doing so should be recorded. In these cases the participants remain within&#xD;
      the study for the purposes of follow-up and data analysis. All participants are free to&#xD;
      withdraw at any time from the protocol treatment without giving reasons and without&#xD;
      prejudicing further treatment.&#xD;
&#xD;
      CONFIDENTIALITY The Chief Investigator will preserve the confidentiality of participants&#xD;
      taking part in the study and is registered under the Data Protection Act.&#xD;
&#xD;
      PUBLICATION POLICY Data ownership rights will lie with the institution. Findings of this&#xD;
      study will be presented as a Dissertation and will be available through Open Access. The&#xD;
      investigators aim to publish findings in peer-review journals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Actual">September 26, 2019</completion_date>
  <primary_completion_date type="Actual">August 14, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Antibiotic Courses</measure>
    <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
    <description>Treatments due to respiratory exacerbations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Hospitalsations Due to Respiratory Exacerbations</measure>
    <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
    <description>Number of respiratory exacerbations that required not planned hospitalisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant's Perception of Treatment</measure>
    <time_frame>At 12 months after starting treatment with hypertonic saline</time_frame>
    <description>Questionnaire: &quot;Hypertonic saline treatment questionnaire&quot;. Perception of overall usefulness of nebulised hypertonic saline: &quot;Useful&quot;, &quot;Not useful&quot;, &quot;I don't know&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent's or Legal Guardian's Perception of Treatment</measure>
    <time_frame>At 12 months after starting treatment with hypertonic saline</time_frame>
    <description>&quot;Hypertonic saline treatment questionnaire for legal guardian&quot;. Measures the perception of overall usefulness of nebulised hypertonic saline through a likert scale: Very useful, useful, neither useful or not useful, not useful, not at all useful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on the Ease of Airway Clearance Pictorial Analogue Scale From Children and Young Adults as Participants</measure>
    <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
    <description>Pictorial visual scale &quot;Facial Rating of perceived exertion Scale&quot;. Measures ease of airway clearance. Values range starting in 0 (Extremely easy) to 10 (Extremely hard), including 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Numbers are also associated with facial expressions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on the Ease of Airway Clearance From Parents or Legal Guardians</measure>
    <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
    <description>Measures ease of airway clearance through a 1-5 likert scale: 1) Very easy, 2) Easy, 3) Neither easy nor difficult, 4) Not easy, 5) Not at all easy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea Index (AI)</measure>
    <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
    <description>The number of apneas recorded during the study per hour of sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AHI</measure>
    <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
    <description>Nocturnal Apnoea Hipopnea index: total number of apnea events plus hypopnea events divided by the total number of minutes of actual sleep time and then multiplied by 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%SpO2</measure>
    <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
    <description>Nocturnal oxygen saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal ODI</measure>
    <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
    <description>Oxygen desaturation index: Number of desaturations per hour of sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TcPCO2</measure>
    <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
    <description>Nocturnal Transcutaneous Carbon Dioxide in kPa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC %Predicted Rate of Decline</measure>
    <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
    <description>Rate of decline per year of Tiffenau index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1% Predicted Rate of Decline</measure>
    <time_frame>Change from the baseline (before treatment) and 12 months after treatment</time_frame>
    <description>Rate of decline of Forced Expiratory Volume in first second (FEV1) percentage of predicted.&#xD;
Rate of decline is a measure of slope of FEV1 percentage predicted.&#xD;
Baseline slope: [(FEV1% at baseline / FEV1% 12 months before treatment) - 1] * 100 After treatment slope: [(FEV1% 12 months after treatment / FEV1% at baseline) - 1] * 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC% Predicted Rate of Decline</measure>
    <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
    <description>Rate of decline of Forced Vital Capacity (FVC) percentage of predicted. Rate of decline is a measure of slope of FVC%.&#xD;
Baseline slope: [(FVC% at baseline / FVC% 12 months before treatment) - 1] * 100 After treatment slope: [(FVC% 12 months after treatment / FVC% at baseline) - 1] * 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF)</measure>
    <time_frame>Change from baseline peak expiratory flow at 12 months after starting treatment with hypertonic saline</time_frame>
    <description>Peak expiratory flow percentage of predicted</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Neuromuscular Diseases</condition>
  <arm_group>
    <arm_group_label>Before treatment</arm_group_label>
    <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After treatment</arm_group_label>
    <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulised hypertonic saline</intervention_name>
    <description>Nebulised hypertonic saline used for a period of at least 12 months</description>
    <arm_group_label>After treatment</arm_group_label>
    <other_name>3% Sodium Chloride</other_name>
    <other_name>5% Sodium Chloride</other_name>
    <other_name>7% Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with Neuromuscular disease or Cerebral Palsy who have their care at the Royal&#xD;
        Brompton Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children with Neuromuscular disease or Cerebral Palsy who have been on treatment with&#xD;
             nebulised Hypertonic Saline for at least 12 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children also diagnosed with cystic fibrosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Natalia Galaz Souza, Professional</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW36NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Allen J. Pulmonary complications of neuromuscular disease: a respiratory mechanics perspective. Paediatr Respir Rev. 2010 Mar;11(1):18-23. doi: 10.1016/j.prrv.2009.10.002. Epub 2009 Dec 2.</citation>
    <PMID>20113987</PMID>
  </reference>
  <reference>
    <citation>Lo Mauro A, Aliverti A. Physiology of respiratory disturbances in muscular dystrophies. Breathe (Sheff). 2016 Dec;12(4):318-327. doi: 10.1183/20734735.012716.</citation>
    <PMID>28210319</PMID>
  </reference>
  <reference>
    <citation>Boitano LJ. Management of airway clearance in neuromuscular disease. Respir Care. 2006 Aug;51(8):913-22; discussion 922-4. Review.</citation>
    <PMID>16867201</PMID>
  </reference>
  <reference>
    <citation>Gerdung CA, Tsang A, Yasseen AS 3rd, Armstrong K, McMillan HJ, Kovesi T. Association Between Chronic Aspiration and Chronic Airway Infection with Pseudomonas aeruginosa and Other Gram-Negative Bacteria in Children with Cerebral Palsy. Lung. 2016 Apr;194(2):307-14. doi: 10.1007/s00408-016-9856-5. Epub 2016 Feb 16.</citation>
    <PMID>26883134</PMID>
  </reference>
  <reference>
    <citation>Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2001 Dec 15;164(12):2191-4.</citation>
    <PMID>11751186</PMID>
  </reference>
  <reference>
    <citation>Bell CF, Kurosky SK, Candrilli SD. Muscular dystrophy-related hospitalizations among male pediatric patients in the United States. Hosp Pract (1995). 2015;43(3):180-5. doi: 10.1080/21548331.2015.1033375. Epub 2015 Apr 1.</citation>
    <PMID>25833749</PMID>
  </reference>
  <reference>
    <citation>Yuan JX, McGowan M, Hadjikoumi I, Pant B. Do children with neurological disabilities use more inpatient resources: an observational study. Emerg Themes Epidemiol. 2017 Apr 27;14:5. doi: 10.1186/s12982-017-0059-1. eCollection 2017.</citation>
    <PMID>28465710</PMID>
  </reference>
  <reference>
    <citation>Elkins MR, Bye PT. Mechanisms and applications of hypertonic saline. J R Soc Med. 2011 Jul;104 Suppl 1:S2-5. doi: 10.1258/jrsm.2011.s11101. Review.</citation>
    <PMID>21719889</PMID>
  </reference>
  <reference>
    <citation>Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006 Jan 19;354(3):229-40.</citation>
    <PMID>16421364</PMID>
  </reference>
  <reference>
    <citation>Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax. 2010 May;65(5):379-83. doi: 10.1136/thx.2009.125831.</citation>
    <PMID>20435858</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <results_first_submitted>July 22, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertonic saline</keyword>
  <keyword>nebulised</keyword>
  <keyword>children</keyword>
  <keyword>young people</keyword>
  <keyword>adolescents</keyword>
  <keyword>respiratory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data ownership rights will lie with the institution.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03623698/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Children and Young People With Neuromuscular Disease</title>
          <description>Children and young people with neuromuscular disease 18 years old or younger, who had been at least 12 months on prescribed nebulised saline (0.9%, 3%, 6%, and/or 7%) between 2011 and 2019.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Children and Young People With Neuromuscular Disease</title>
          <description>Children and young people with neuromuscular disease before nebulised saline was prescribed to them.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>SMA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chromosomal myopathy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myotubular myopathy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nemaline Rod myopathy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congenital muscular dystrophy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LGMD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joubert syndrome</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle eye brain disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rett syndrome</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other characteristics</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-ambulant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tracheotomised</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrostomy feeding</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scoliosis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other treatments and medical procedures</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Antibiotic prophylaxus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dornase alpha</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Home mechanical ventilation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mechanically assisted cough</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tonicity of nebulised prescribed</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hypertonic saline only (3%, 6%, 7%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Isotonic saline only (0.9%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combination of hypertonic and isotonic saline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Antibiotic Courses</title>
        <description>Treatments due to respiratory exacerbations</description>
        <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
        <population>Two participants had incomplete data for this outcome, and/or their parents could not recall</population>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9%, 3%, 6%, and/or 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Antibiotic Courses</title>
          <description>Treatments due to respiratory exacerbations</description>
          <population>Two participants had incomplete data for this outcome, and/or their parents could not recall</population>
          <units>Courses of antibiotics</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total courses of antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Courses of Oral antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Courses of intravenous antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed using IBM SPSS Statistics software, version 25.&#xD;
This analysis applies to the category of Total courses of antibiotics.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-2.500</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.000</ci_lower_limit>
            <ci_upper_limit>-1.500</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed using IBM SPSS Statistics software, version 25.&#xD;
This analysis applies to the category of Total courses of antibiotics.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Linear mixed-effects model</non_inferiority_desc>
            <p_value>0.001</p_value>
            <p_value_desc>95% confidence interval, significance level p-values &lt;0.05. Random effects pre-defined from theory and published data, and AIC was were used to define the best model. Outcome measures: Courses of antibiotics; Fixed effect: nebulised saline treatment.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random effects: age, gender, mechanical ventilation, tracheostomy, gastrostomy, non-ambulant.</method_desc>
            <param_type>Restricted Maximum Likelihood (REML)</param_type>
            <param_value>-2.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.46</ci_lower_limit>
            <ci_upper_limit>-1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Hospitalsations Due to Respiratory Exacerbations</title>
        <description>Number of respiratory exacerbations that required not planned hospitalisation</description>
        <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
        <population>23/24 patients were analysed for this outcome, because one patient had incomplete records on hospitalisations.</population>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9%, 3%, 6%, and/or 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalsations Due to Respiratory Exacerbations</title>
          <description>Number of respiratory exacerbations that required not planned hospitalisation</description>
          <population>23/24 patients were analysed for this outcome, because one patient had incomplete records on hospitalisations.</population>
          <units>Hospitalisations</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed using IBM SPSS Statistics software, version 25.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.50</ci_lower_limit>
            <ci_upper_limit>-0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed using IBM SPSS Statistics software, version 25.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>95% confidence interval, significance level p-values &lt;0.05. Random effects pre-defined from theory and published data, and AIC was were used to define the best model. Outcome measures: Courses of antibiotics; Fixed effect: nebulised saline treatment.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random effects: age, gender, prolonged mechanical ventilation (nasal or tracheostomy), and antibiotic prophylaxis</method_desc>
            <param_type>Restricted Maximum Likelihood (REML)</param_type>
            <param_value>-1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.53</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant's Perception of Treatment</title>
        <description>Questionnaire: &quot;Hypertonic saline treatment questionnaire&quot;. Perception of overall usefulness of nebulised hypertonic saline: &quot;Useful&quot;, &quot;Not useful&quot;, &quot;I don't know&quot;.</description>
        <time_frame>At 12 months after starting treatment with hypertonic saline</time_frame>
        <population>Applied to all participants aged 10-15 years who were able to communicate their views.</population>
        <group_list>
          <group group_id="O1">
            <title>Children and Young People With Neuromuscular Disease</title>
            <description>Children and young people with neuromuscular disease 18 years old or younger, who had been at least 12 months on prescribed nebulised saline (0.9%, 3%, 6%, and/or 7%) between 2011 and 2019.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant's Perception of Treatment</title>
          <description>Questionnaire: &quot;Hypertonic saline treatment questionnaire&quot;. Perception of overall usefulness of nebulised hypertonic saline: &quot;Useful&quot;, &quot;Not useful&quot;, &quot;I don't know&quot;.</description>
          <population>Applied to all participants aged 10-15 years who were able to communicate their views.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Useful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not useful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I don't know</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parent's or Legal Guardian's Perception of Treatment</title>
        <description>&quot;Hypertonic saline treatment questionnaire for legal guardian&quot;. Measures the perception of overall usefulness of nebulised hypertonic saline through a likert scale: Very useful, useful, neither useful or not useful, not useful, not at all useful.</description>
        <time_frame>At 12 months after starting treatment with hypertonic saline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Parent's or Legal Guardians</title>
            <description>One parent or legal guardian for each of the study participants</description>
          </group>
        </group_list>
        <measure>
          <title>Parent's or Legal Guardian's Perception of Treatment</title>
          <description>&quot;Hypertonic saline treatment questionnaire for legal guardian&quot;. Measures the perception of overall usefulness of nebulised hypertonic saline through a likert scale: Very useful, useful, neither useful or not useful, not useful, not at all useful.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very useful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>useful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>neither useful or not useful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not useful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not at all useful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score on the Ease of Airway Clearance Pictorial Analogue Scale From Children and Young Adults as Participants</title>
        <description>Pictorial visual scale &quot;Facial Rating of perceived exertion Scale&quot;. Measures ease of airway clearance. Values range starting in 0 (Extremely easy) to 10 (Extremely hard), including 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Numbers are also associated with facial expressions.</description>
        <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>Score on the Ease of Airway Clearance Pictorial Analogue Scale From Children and Young Adults as Participants</title>
          <description>Pictorial visual scale &quot;Facial Rating of perceived exertion Scale&quot;. Measures ease of airway clearance. Values range starting in 0 (Extremely easy) to 10 (Extremely hard), including 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Numbers are also associated with facial expressions.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" lower_limit="4" upper_limit="9"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-4.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.50</ci_lower_limit>
            <ci_upper_limit>-3.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score on the Ease of Airway Clearance From Parents or Legal Guardians</title>
        <description>Measures ease of airway clearance through a 1-5 likert scale: 1) Very easy, 2) Easy, 3) Neither easy nor difficult, 4) Not easy, 5) Not at all easy.</description>
        <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Parents of children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Parents pf children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>Score on the Ease of Airway Clearance From Parents or Legal Guardians</title>
          <description>Measures ease of airway clearance through a 1-5 likert scale: 1) Very easy, 2) Easy, 3) Neither easy nor difficult, 4) Not easy, 5) Not at all easy.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="2.13" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>-2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apnea Index (AI)</title>
        <description>The number of apneas recorded during the study per hour of sleep</description>
        <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
        <population>3/24 patients had records for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9%, 3%, 6%, and/or 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>Apnea Index (AI)</title>
          <description>The number of apneas recorded during the study per hour of sleep</description>
          <population>3/24 patients had records for this outcome</population>
          <units>Events per hour of sleep</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="1.02"/>
                    <measurement group_id="O2" value="0.40" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AHI</title>
        <description>Nocturnal Apnoea Hipopnea index: total number of apnea events plus hypopnea events divided by the total number of minutes of actual sleep time and then multiplied by 60.</description>
        <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>AHI</title>
          <description>Nocturnal Apnoea Hipopnea index: total number of apnea events plus hypopnea events divided by the total number of minutes of actual sleep time and then multiplied by 60.</description>
          <units>Events per hour of sleep</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.53" spread="1.70"/>
                    <measurement group_id="O2" value="1.38" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>%SpO2</title>
        <description>Nocturnal oxygen saturation</description>
        <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
        <population>21/24 patients had complete records for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9%, 3%, 6%, and/or 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>%SpO2</title>
          <description>Nocturnal oxygen saturation</description>
          <population>21/24 patients had complete records for this outcome</population>
          <units>percentage of SpO2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.55" spread="1.92"/>
                    <measurement group_id="O2" value="96.53" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nocturnal ODI</title>
        <description>Oxygen desaturation index: Number of desaturations per hour of sleep</description>
        <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
        <population>21/24 patients had complete records for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>Nocturnal ODI</title>
          <description>Oxygen desaturation index: Number of desaturations per hour of sleep</description>
          <population>21/24 patients had complete records for this outcome</population>
          <units>Events per hour of sleep</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="3.42"/>
                    <measurement group_id="O2" value="3.32" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.26</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TcPCO2</title>
        <description>Nocturnal Transcutaneous Carbon Dioxide in kPa</description>
        <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
        <population>21/24 patients had complete records for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9%, 3%, 6%, and/or 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>TcPCO2</title>
          <description>Nocturnal Transcutaneous Carbon Dioxide in kPa</description>
          <population>21/24 patients had complete records for this outcome</population>
          <units>Kilopascal (kPa)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.77" spread="0.95"/>
                    <measurement group_id="O2" value="6.00" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1/FVC %Predicted Rate of Decline</title>
        <description>Rate of decline per year of Tiffenau index</description>
        <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
        <population>5/24 patients had complete records for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1/FVC %Predicted Rate of Decline</title>
          <description>Rate of decline per year of Tiffenau index</description>
          <population>5/24 patients had complete records for this outcome</population>
          <units>percentage of predicted</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.37" lower_limit="84.50" upper_limit="110.50"/>
                    <measurement group_id="O2" value="98.89" lower_limit="92.00" upper_limit="109.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1% Predicted Rate of Decline</title>
        <description>Rate of decline of Forced Expiratory Volume in first second (FEV1) percentage of predicted.&#xD;
Rate of decline is a measure of slope of FEV1 percentage predicted.&#xD;
Baseline slope: [(FEV1% at baseline / FEV1% 12 months before treatment) - 1] * 100 After treatment slope: [(FEV1% 12 months after treatment / FEV1% at baseline) - 1] * 100</description>
        <time_frame>Change from the baseline (before treatment) and 12 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1% Predicted Rate of Decline</title>
          <description>Rate of decline of Forced Expiratory Volume in first second (FEV1) percentage of predicted.&#xD;
Rate of decline is a measure of slope of FEV1 percentage predicted.&#xD;
Baseline slope: [(FEV1% at baseline / FEV1% 12 months before treatment) - 1] * 100 After treatment slope: [(FEV1% 12 months after treatment / FEV1% at baseline) - 1] * 100</description>
          <units>percentage of predicted</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.03" lower_limit="-8.67" upper_limit="-8.03"/>
                    <measurement group_id="O2" value="4.00" lower_limit="-2.14" upper_limit="17.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC% Predicted Rate of Decline</title>
        <description>Rate of decline of Forced Vital Capacity (FVC) percentage of predicted. Rate of decline is a measure of slope of FVC%.&#xD;
Baseline slope: [(FVC% at baseline / FVC% 12 months before treatment) - 1] * 100 After treatment slope: [(FVC% 12 months after treatment / FVC% at baseline) - 1] * 100</description>
        <time_frame>Change from baseline (before treatment) and 12 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>FVC% Predicted Rate of Decline</title>
          <description>Rate of decline of Forced Vital Capacity (FVC) percentage of predicted. Rate of decline is a measure of slope of FVC%.&#xD;
Baseline slope: [(FVC% at baseline / FVC% 12 months before treatment) - 1] * 100 After treatment slope: [(FVC% 12 months after treatment / FVC% at baseline) - 1] * 100</description>
          <units>percentage of predicted</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.44" lower_limit="-9.33" upper_limit="-7.44"/>
                    <measurement group_id="O2" value="7.00" lower_limit="-15.43" upper_limit="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF)</title>
        <description>Peak expiratory flow percentage of predicted</description>
        <time_frame>Change from baseline peak expiratory flow at 12 months after starting treatment with hypertonic saline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
          <group group_id="O2">
            <title>After Treatment</title>
            <description>Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF)</title>
          <description>Peak expiratory flow percentage of predicted</description>
          <units>percentage of predicted</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" lower_limit="33" upper_limit="47.5"/>
                    <measurement group_id="O2" value="47" lower_limit="42" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This was a retrospective study. Adverse events data was not collected.</time_frame>
      <desc>This was a retrospective study. Adverse events data was not collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Children and Young People With Neuromuscular Disease</title>
          <description>Children and young people with neuromuscular disease 18 years old or younger, who had been at least 12 months on prescribed nebulised saline (0.9%, 3%, 6%, and/or 7%) between 2011 and 2019.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a retrospective study, with potential for bias from self-selection. Each patient was used as their own control. The use of questionnaires had the potential for recall bias. This study did not have adherence data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mrs. Natalia Galaz Souza</name_or_title>
      <organization>Imperial College London</organization>
      <phone>07751842851</phone>
      <email>natalia.galaz-souza16@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

